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Abstract
The linear ends of chromosome are protected by specialized ribonucleoprotein (RNP)
termed as telomere. These specialized terminal elements with tandem repeated sequence
are the protective cap that alleviate end replication problem and cell senescence. The
telomere length maintenance is essential to avoid cell death and apoptosis. Telomere
shortening has been related to chronic stress due to several factors, which include not only
psychological  stress  but  also  diseases  such  as  cardiovascular  diseases  and cancer.
Telomerase enzyme which maintains telomere length is the major factor responsible for
evading cell death. Telomere length maintenance and telomerase expression put together
are the prerequisite for immortality, an essential character for cancer cells. Understanding
the mechanism of telomere and telomerase functions paves way for eradicating the
diseases such as cancer.
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1. Introduction
Telomeres are specialized DNA structures consisting of tandem arrays of hexa-nucleotide
(TTAGGG) DNA sequences that cap the end of chromosomes. These structures residing near
the ends of chromosomes play a very vital role in maintaining the integrity of the whole genome
and prevent the loss of genetic material. As a consequence of cell division, short stretches of
DNA will be lost from telomeric region and eventually lead to cellular senescence and death.
There are a lot of evidences to suggest that telomere length is a better biomarker for overall
health status, compared to the currently used biomarkers for the same. Few of the phenomena
regarding the telomere length are unanswered till now. Till date it is unclear about the mechanistic
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regarding the telomere length are unanswered till now. Till date it is unclear about the mechanistic
correlation between telomere size and life span of various species. To prevent senescence of cell,
the preservation of telomere length is essential, which is maintained by telomerase enzyme.
Telomerase is a reverse transcriptase enzyme which has recently emerged as an attractive target
for cancer as it is a crucial factor required for the tumor immortalization of a subset of cells,
including cancer stem cells.  Studies have proved that 80–85% of the tumor cells express
telomerase whereas somatic cells lack the expression of telomerase [1]. The important paradox
is that telomerase-negative normal cells have lengthier telomeres than telomerase-positive
cancer cells [2]. Thus difference in telomere length and cell kinetics between normal and cancerous
cells shows that targeting telomerase is a more effective way to target cancer cells. Owing to the
significant role of telomere and telomerase in tumor immortalization understanding their
amassed influence on cancer is crucial for cancer therapy. In this context, this book chapter is
focused on disseminating the integrated impact of telomere and telomerase on cancer progres-
sion.
2. Telomere construction
The basic structure of telomere is conserved among eukaryotes and consists of short tandem
DNA repeats, with G-rich sequence at the three-end referred to as the G-strand and the
complementary strand is called the C-strand at the five-end (Figure 1) [3]. The length of
telomeric DNA varies from 2 to 20 kilobase pairs, depending on factors such as tissue type and
human age [4]. The telomere is conspicuous owing to the presence of G-overhang which
extends beyond its complementary C-rich strand to form a single-stranded overhang, termed
the G-tail. It has been proposed that the 3′ G-overhang can be sequestered into a lasso-like
structure known as the T-loop (Figure 2) [5, 6]. The single-stranded G-overhang invades the
double-stranded telomeric DNA, which displaces the bound G-strand base-pairing with the
C-strand. As this displaced binding takes place at a distance from the physical end of the
telomere, it generates a large duplex structure called the T-loop (Figure 2) [3, 5].
Figure 1. Telomeric DNA.
Telomeres can also fold into G-quadruplex DNA, an unusual DNA conformation that is based
on a guanine quartet [7]. The repetitive and GC-rich nature of telomeric DNA endows it with
the capability to form the higher-order DNA conformation, G-quadruplexes [8, 9]. To maintain
such unusual structure of telomeres, a set of telomeric protein complex has evolved, termed
shelterin. The shelterin complex consists of six individual proteins, telomeric repeat binding
factor 1 (TRF1), TRF2, repressor/activator protein 1 (RAP1), TIN2 (TRF1 interacting protein 2),
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TPP1 (TINT1/PIP1/PTOP 1), and protection of telomeres 1 (POT1) [6, 10]. The proteins TRF1
and TRF2 attach to double-stranded telomeric repeats facilitating the anchoring of the complex
along the length of telomeres [11–14], whereas POT1 binds to the single-stranded overhang.
TPP1 and TIN2 act as bridging proteins between the above DNA-binding modules and are
crucial for chromosome end protection and telomere length regulation. TRF1 and TRF2 with
the help of TIN2 [15] bind with POT1 via TPP1 [16–19]. TIN2 also connects TRF1 to TRF2, and
this interaction contributes to the stabilization of TRF2 on telomeres [17–19]. Besides this
shelterin complex, other proteins like TEN1 and Pinx1, which are not telomere specific, are
also present at telomeres and carry out important functions in recruitment of telomerase [20].
Figure 2. T-loop formation.
Figure 3. Telomere-telomerase assembly.
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3. Telomere: a knight cap
During the evolvement of linear genome, the natural ends of linear chromosomes resemble
DNA breaks and tend to induce DNA damage response (DDR). These natural linear ends are
protected by the sequestration of the ribonucleoprotein (RNP) sequence, telomeres which
mask the ends from continuous exposure to the DNA damage response (DDR). Telomeres
serve as protective caps, preventing the chromosomal ends from being recognized as double-
strand breaks by the DNA damage repair system and the activation of the p53 or p16INK4a
pathway and the start of senescence or apoptosis. If the telomere cap is removed, genome
instability is induced. Telomeres with its tightly regulated complexes consisting of repetitive
G-rich DNA and specialized proteins accomplish the task of not only concealing the linear
chromosome ends from detection and undesired repair, but also protect from checkpoints,
homologous recombination, end-to-end fusions, or other events that normally promote repair
of intra-chromosomal DNA breaks acts [21]. Telomeric proteins and their interacting factors
create an environment at chromosome ends that inhibits DNA repair at that point; however,
the repair machinery is also essential for proper telomere function.
The closed configuration of the T-loop of telomeric region provides a protective cap that defines
the natural end of the chromosome and masks the telomere from the DDR machinery (Figure
2) [6]. In particular, T-loops could provide an architectural solution to the repression of the
ataxia telangiectasia mutated (ATM) kinase pathway, which relies on a sensor (the MRN
(Mre11/Rad50/Nbs1) complex) with DNA end-binding activity. In addition, T-loops could
prevent the Ku70/80 heterodimer, a DNA repair factor that binds to DNA ends, from loading
onto the telomere terminus, thereby blocking the initiation of the non-homologous end-joining
(NHEJ) pathway (Figure 4).
Figure 4. DNA damage response pathway.
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Among the DNA-binding proteins, TRF1 has DNA remodeling activity [5, 22] and also shown
to promote efficient replication of telomeres [23, 24]. On the contrary, TRF2 engages in
chromosome end protection by inducing topological changes in telomeric DNA [25], T-loop
assembly [26, 27] and by suppression of ATM dependent DDR and NHEJ (Figure 4) [28, 29].
Besides that, TRF2 plays a critical role in chromatin assembly, which was demonstrated by the
observation that overexpression of TRF2 resulted in aberrant nucleosome spacing and
decreased abundance of the core histones H3 and H4 at chromosome ends [30]. TRF2 lacking
cells are reported to be growth arrested because of up-regulation of p53 and also show other
hallmarks of ATM signaling, including the phosphorylation of ATM and Chk2 [31, 32]. Among
the two DDR, the ATM kinase pathway at telomeres is repressed by TRF2 subunit, whereas
POT1 is responsible for protection of telomere by suppression of ATR (ATM Rad3-related
protein)-dependant DDR pathways [28, 33].
The high affinity of POT1 for single-stranded telomeric DNA makes it a G-strand binding
component displaced from the T-loop and forms a closed configuration locking in the struc-
ture (Figure 2). Earlier report models suggest that POT1 and TPP1 compete with telomerase
for access to the overhang [33]. Contrarily, direct interaction between TPP1 and telomerase
bolsters telomerase processivity [34, 35] whereas increased loading of POT1 along the over-
hang block telomerase accessibility to the 3′-OH substrate. The role of RAP1 is obscure and its
function has recently been elucidated. The presence of RAP1 at telomeres appears as a backup
mechanism to prevent NHEJ when topology-mediated telomere protection is impaired [36].
In case of mutation in TRF2 which wraps the DNA, RAP1 has been implicated in the inhibition
of NHEJ [37, 38].
Thus physically taken together, the shelterin complex and G-overhang of telomere are the
protective cap that have an immensely complex role in convergence of end protection and
telomere length maintenance mechanisms.
4. Telomerase activity
With each cell division, telomere length is reduced by ~50 to 200 bp [39] primarily because the
lagging strand of DNA synthesis is unable to replicate the extreme 3′ end of the chromosome
which is denoted as end replication problem [40, 41]. When telomeres become sufficiently
short, cells enter an irreversible growth arrest called cellular senescence. In most eukaryotes,
telomeres are stabilized, and the shortening telomeric DNA is replenished, by the action of the
RNP reverse transcriptase telomerase. Progressive telomere loss has been experimentally
demonstrated using non-immortalized cells in culture that lack detectable telomerase [42, 43].
In cells with active telomerase, such as cancer cells, the telomere length is continually being
built up and shortened in a regulated way that maintains telomere length homeostasis and
retains telomere functionality. Shortening of telomeres occur due to nucleolytic degradation
and incomplete DNA replication. On the contrary, lengthening is primarily accomplished by
the action of a specialized reverse transcriptase called telomerase [44] and occasionally by
homologous recombination (HR) [45]. Telomerase uses the 3′ G-rich strand of a chromosome
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as primer to elongate chromosome end by reverse-transcribing the template region of its tightly
associated RNA moiety and coordinative action with the DNA replication machinery [44, 46].
For lengthening activity, telomerase requires not only hTERT catalytic subunit and RNA
template (hTR) but also other factors [47, 48].
The 3′ half of the hTR resembling the box H/ACA family of small nucleolar RNAs (snoRNAs)
[49, 50] is essential for proper 3′-end processing, stability and nucleolar targeting in vivo [44].
The 5′ end of hTR not only acts as template for the telomere extension at chromosome ends [5,
51] but also serves as a pseudoknot that is likely to be important for telomerase function (5,
49). A 6 bp U-rich sequence at the 5′ end of hTR also interacts directly with hnRNPs C1 and
C2 (Figure 3) [52]. Even though hTR is highly expressed in all tissues regardless of telomerase
activity [53], in cancer cells hTR is generally expressed fivefold higher than normal cells [54].
However, the expression (mRNA) of the telomeric catalytic component hTERT which is closely
associated with telomerase activity is estimated to be less than one to five copies per cell [54].
hTERT is generally repressed in normal cells and up-regulated in immortal cells, suggesting
that hTERT is the primary determinant for the enzyme activity.
Figure 5. Telomerase complex.
It has been suggested that in addition to telomere elongation another aspect of telomerase RNP
function is to allow even short telomeres to remain functional, which in the absence of
telomerase would have caused cells to stop dividing or led to telomere–telomere fusions [55].
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In other words, telomerase permits cell proliferation by stabilizing short telomeres that would
be unstable in the absence of functional telomerase. In recent years, evidence has accumulated
that telomerase, and in particular its catalytic subunit TERT, is involved in various non-
telomere-related functions such as regulation of gene expression, growth factors and cell
proliferation [56–61]. It has been reported that the telomerase has a role in modulation of Wnt/
β-catenin pathway [60]. TERT has been demonstrated to bind to TBE-containing promoter
elements, the specific chromatin sites of Wnt/β-catenin target genes, forming a part of the β-
catenin transcriptional complex, which was facilitated by interaction with BRG1. These data
endorsed the precipitous role for telomerase as a transcriptional modulator of Wnt/β-catenin
signaling pathway involved in progenitor cell regulation.
In addition, various groups have shown that TERT shuttles from the nucleus and translocates
to mitochondria upon exogenous stress [62–67]. Singhapol and his coworkers have demon-
strated that mitochondrial telomerase localization specifically decreases mitochondrial ROS
generation and cellular oxidative stress after induction of exogenous stress generated by
H2O2 or irradiation in cancer cells and might thereby prevent damage to nuclear DNA [68].
Thus the presence of telomerase not only maintains telomere length imparting immortality
but also play multifarious role in tumorigenesis via non-telomere-dependent mechanism
which demonstrated the imperative ubiquity of telomerase in cancer cells.
5. Skewed expression of telomerase
Telomerase, the RNA-dependent DNA polymerase by preventing the shortening of telomeric
DNA sequences, accouters unlimited proliferation. As per the telomere hypothesis of cancer
cell immortalization, telomere shortening limits the life span of telomerase-negative normal
cells, whereas telomerase activation in cancer cells extends their life span [4]. In normal human
cells, telomerase activity is quenched during embryonic differentiation [69]. On the contrary
in some tissues, like male germ cells, activated lymphocytes, and certain types of stem cell
populations, the telomerase activity is induced [15, 70]. Owing to its diverse activity, the
telomerase [71] which was established to be absent in most of the normal human somatic cells
is recorded to be expressed in more than 90% of cancerous cells and in vitro-immortalized cells
[15, 70]. A study showed that while most of the glioma tissues possess increased telomerase
activity, only few (10%) anaplastic astrocytomas are reported to be telomerase positive [72–
74]. In contrast to most cancerous cells, the telomerase expression is present in only 50% of
glioblastoma and retinoblastoma samples, and activity is even rarely found in meningiomas
and astrocytomas [75, 76].
Induction of telomerase activity in primary human keratinocytes and mammary epithelial cells
has been attributed to the effect of human papillomavirus 16 E6 protein [77]. Similarly, during
the menstrual cycle involving the proliferation of endometrial cells, telomerase activity is
detected in normal human endometrium [78, 79]. These reports emphasis that telomerase
might be the reason for tumorigenesis in hormone-dependent cancers.
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It has been suggested that up-regulated expression of telomerase is contributed by the
increased copy number of hTERT which was demonstrated by the report that while hTERT
protein expression was strongly positive in tumor cells, the expression of hTERT in non-
neoplastic mucosal cells as well as stromal elements (except lymphocytes) was weak or
negative [80]. In most cases, hTERT expression is closely correlated not only with telomerase
activity but also with cancer initiation and progression. In head and neck squamous cell
carcinoma and human glioma cell lines, there was decrease in telomerase activity which has
been correlated with overexpression of p53, E2F, p16, p21, and p15 individually [81, 82]. In
malignant and nonmalignant human hematopoietic cell lines, primary leukemic cells, and
normal T lymphocytes, IFN-α is reported to inhibit telomerase activity by suppressing hTERT
transcription [83]. In addition to growth and differentiation-related regulation, telomerase
activity is subject to regulation by other external and intracellular factors such as UV irradia-
tion [84]. The telomerase having influence over several signaling pathways that determine cell
proliferative or death responses when overexpressed might abrogate anti-proliferative or cell
death signals. Thus cancer cells with high levels of telomerase might gain a selective growth
advantage.
6. Telomerase as biomarker of cancer
Advent of latest cancer biomarkers has increased opportunities for improving cancer diag-
nostics by enhancing the quickness of detection and efficacy of treatment. In relation to the
practice of new therapeutic interventions, proficient biomarkers are helpful in detection and
prediction of remission or relapse of cancer at both gross and molecular levels. Telomerase
activity is a hallmark of most cancer biopsies, but not generally detected in premalignant
lesions and in normal tissue samples except germ cells and hematopoietic stem cells. Thus
telomerase activity can be a promising biomarker for diagnosis of malignancies and a target
for chemotherapy or gene therapy. Extent of telomerase activity in tumor tissues may be
prognostic indicators of patient outcome. Thus, at the present time telomerase is being studied
in anticipation of clinical usage. Many clinical trials for telomerase assay in cancer diagnosis
are under trial. Fresh or fresh-frozen biopsies, fluids, and secretions are subject for these trials.
Other components of telomerase enzyme complex have also been utilized as biomarkers for
telomerase activity. The expression of the RNA subunit of the telomerase complex (hTR) is also
regarded as a diagnostic marker [85]. But the expression of hTR does not always correlate with
telomerase protein expression in that particular cell type. hTR can be constitutively expressed
in certain cell types in which even telomerase activity is not present [86]. Apart from this,
mutation in genes of telomerase and associated proteins are considered as a diagnostic and
prognostic marker for many genetic abnormalities collectively termed as telomeropathies.
Early-onset melanoma tumor syndrome with multiple co-morbid cancers can be predicted
from telomerase gene promoter mutation analysis. In this disorder, the mutation in promoter
of telomerase gene introduces an erythroblast transformation-specific transcription factor-
binding site, resulting in approximately twofold up-regulation of telomerase [87].
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Introduction of telomeric repeat amplification protocol (TRAP) assay has facilitated the de-
tection of telomerase activity in tumor biopsy samples as well as cell lines [88]. Specificity of
telomerase activity in malignant phenotype further enforces the reliability of this assay. The
most important advantage of TRAP assay is its low detectable limit. TRAP assay has al-
lowed the analysis of minimal tissue samples, such as fine-needle aspirates of the breast and
thyroid, cervical smears, oral washings, and urine [89, 90]. Telomerase also has been used to
detect circulating tumor cells also [85]. Newly emerged technique, droplet digital TRAP as-
say can detect telomerase activity even in a single cell [91]. However, the positive ratios of
detection of telomerase vary in sedimented cells obtained from secretion, washing, brushing
samples, etc. Electrochemical telomerase assay (ECTA) is another newly emerged technique
to detect telomerase activity in biological samples [92]. It is comparatively simple and rapid
PCR-free method. ECTA consists of a TS primer-immobilized electrode and ferrocenyl
naphthalene diimide derivative as a tetraplex binder. This method has shown a high effi-
ciency of telomerase detection in oral cancer biopsies [93]. Taken in account of all these re-
ports, telomerase and its functionality can be utilized as a promising diagnostic and
prognostic method in cancer.
7. Telomeres in prognosis
Better understanding of telomere structure and its dynamics focused the research on telomeres
as biomarkers for several diseases especially in early detection and prognosis of cancers. A
reduced telomere length in human hematopoietic tumors predicts a reduced survival time in
patients suffering from myeloid leucaemia [94], chronic lymphocytic leucaemia [95], and
myelodysplastic syndromes [96]. Although telomere length in solid tumors is suggested as a
potential prognostic marker, patient survival rates vary with different cancer types. For
example, a short telomere length in prostate cancer correlates with short disease-free interval
and shorter overall survival time [97]. Analysis of telomere length of blood cells is also
considered as predictive markers for pulmonary and esophageal neoplasia as well as of
lymphoma in humans [98]. It has been suggested that the reduced TL in these patients reflects
the effects of increased oxidative stress which correlates with cancer risk. Advent of latest
technologies to measure relative and absolute telomere lengths has paved the way to use
telomere length as diagnostic and prognostic markers. Telomere restriction fragment assay,
qFISH, flow FISH, qPCR assay, single telomere length analysis (STELA), and dot-blot telomere
assay are the currently available assay methods for telomere length [99].
8. Telomerase as drug target
Telomerase enzyme has recently emerged as an attractive target for cancer as it is a crucial
factor required for the tumor immortalization of a subset of cells, including cancer stem cells.
Studies have shown that 80–85% of the tumor cells express telomerase, whereas somatic cells
lack the expression of telomerase [1]. In the present scenario, the major concern about the
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chemotherapeutic approaches is the specificity of action and side effects of drugs on normal
cells. Difference in telomere length and cell kinetics between normal and cancerous cells shows
that targeting telomerase is an effective system to target cancer cells specifically [100]. Although
telomerase is not considered as an oncogene, the expression of telomerase is the major reason
for the transformation of a normal cell to cancer cell [80]. Compared to most other cancer
targets, telomerase antagonists are advantageous due to the wide expression of this enzyme
in cancer types [1]. Telomerase also possesses extra telomeric functions which are very crucial
for tumor survival and homeostasis [101]. Studies have shown that telomerase-based cancer
therapies are less likely to develop resistance against the drugs compared to drugs which target
growth factor receptors or signal-transducing enzymes in cancer cells [2]. This ensures that
cancer drugs based on telomerase inhibition are non-cytotoxic anticancer approach and have
a broad therapeutic value.
9. Conclusion
Maintenance of telomere length in cancer cells is a critical factor in imparting the ability to
undergo uncontrolled multiplication and thus immortality to the cells. It is imperative to
discern the factors involved in telomere length preservation. Understanding the influence of
telomerase and other factors in sustaining telomere length in cancer cells paves way for
perceiving the theranostic role of telomere and telomerase in cancer treatment. Besides the
theranostic effect, the possible side effects could be determined leading to precautionary
methods to nullify the negative impact.
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